Development of a Pediatric Cardiac Mechanical Support Program

The development of a pediatric cardiac support program is a complex, multidisciplinary project. This study describes the University of Iowa Congenital Heart Program's experience from its inception to the present. In, we examine those specific factors that have led to substantial improvements in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Artificial organs 2018-04, Vol.42 (4), p.444-451
Hauptverfasser: Kashyap, Abhishek, Turek, Joseph W., Wagner, Samantha J., Felderman, Laura, Jaggers, Elizabeth A., Gruber, Peter J., Edens, R. Erik
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 451
container_issue 4
container_start_page 444
container_title Artificial organs
container_volume 42
creator Kashyap, Abhishek
Turek, Joseph W.
Wagner, Samantha J.
Felderman, Laura
Jaggers, Elizabeth A.
Gruber, Peter J.
Edens, R. Erik
description The development of a pediatric cardiac support program is a complex, multidisciplinary project. This study describes the University of Iowa Congenital Heart Program's experience from its inception to the present. In, we examine those specific factors that have led to substantial improvements in the program, additionally identifying where further gains can be made. We retrospectively reviewed all pediatric patients who received mechanical cardiac support at the University of Iowa from the inception of the program in 1991. In total, 29 patients received mechanical support between December 1991 and December 2015 and are included in the study. Twelve patients received continuous flow devices and 17 patients received pulsatile flow devices. Median age at implant was 12.8 years (range 0.1–18.2 years). Median weight at implant was 40.5 kg (3.2–123.4 kg). Factors examined included: operating room (OR) time, intensive care unit and hospital length of stay, intubation days, blood product usage, pre‐ and post‐operative bilirubin, creatinine, natriuretic peptide B (NPPB), and device implanted. Categorical and continuous variables were compared using Chi‐squared and Wilcoxon rank‐sum tests, respectively. Of the 29 patients who received mechanical support, 17 (58.6%) were discharged home, 11 (37.9%) died during their hospitalization, and 1 (3.5%) remains hospitalized. Median length of ventricular assist device support was 59.5 days (range 1–653 days). Between December 1991 and December 2011, in‐hospital mortality was 64.3%. Following this period, significant changes were made to patient management with in‐hospital mortality decreasing to 13.3% between February 2013 and December 2015. Comparison between deceased and living patients revealed several significant factors including: median number of packed red blood cells transfused, 8 versus 4 units (P = 0.048), median OR time, 396 versus 299 min (P = 0.003), and device implanted. During the early stages of the mechanical support program, higher than expected mortality rates prompted changes in the management of pediatric cardiac patients, specifically, the development of a dedicated management team. These changes significantly improved outcomes and we suggest can be used as a model for similar cardiac support programs, especially in smaller volume programs.
doi_str_mv 10.1111/aor.12963
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1961034443</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2026099138</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-66898183581423dd9b5e9c708d8c3b0b7ea589dd7b7a7c1c23d81df09fbac87f3</originalsourceid><addsrcrecordid>eNp10E1LwzAYB_AgipvTg19ACl700C1pmjQ5eBjzFZQNX8BbSJNUO9qlJq2yb2-004NgLk8OP_48zx-AQwTHKLyJtG6MEk7xFhgikpAYEZ5ugyFEFMaEps8DsOf9EkKYpZDugkHCESQI4iE4OzfvprJNbVZtZItIRgujS9m6UkUz6cJXRXdGvcpVqWQVPXRNY10bLZx9cbLeBzuFrLw52MwReLq8eJxdx7fzq5vZ9DZWmGAcU8o4QwwThtIEa81zYrjKINNM4RzmmZGEca2zPJOZQioYhnQBeZFLxbICj8BJn9s4-9YZ34q69MpUlVwZ23mBOA3XpGmKAz3-Q5e2c6uwnUhgQiHnCLOgTnulnPXemUI0rqylWwsExVenInQqvjsN9miT2OW10b_yp8QAJj34KCuz_j9JTOf3feQnpLp-bg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2026099138</pqid></control><display><type>article</type><title>Development of a Pediatric Cardiac Mechanical Support Program</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Kashyap, Abhishek ; Turek, Joseph W. ; Wagner, Samantha J. ; Felderman, Laura ; Jaggers, Elizabeth A. ; Gruber, Peter J. ; Edens, R. Erik</creator><creatorcontrib>Kashyap, Abhishek ; Turek, Joseph W. ; Wagner, Samantha J. ; Felderman, Laura ; Jaggers, Elizabeth A. ; Gruber, Peter J. ; Edens, R. Erik</creatorcontrib><description>The development of a pediatric cardiac support program is a complex, multidisciplinary project. This study describes the University of Iowa Congenital Heart Program's experience from its inception to the present. In, we examine those specific factors that have led to substantial improvements in the program, additionally identifying where further gains can be made. We retrospectively reviewed all pediatric patients who received mechanical cardiac support at the University of Iowa from the inception of the program in 1991. In total, 29 patients received mechanical support between December 1991 and December 2015 and are included in the study. Twelve patients received continuous flow devices and 17 patients received pulsatile flow devices. Median age at implant was 12.8 years (range 0.1–18.2 years). Median weight at implant was 40.5 kg (3.2–123.4 kg). Factors examined included: operating room (OR) time, intensive care unit and hospital length of stay, intubation days, blood product usage, pre‐ and post‐operative bilirubin, creatinine, natriuretic peptide B (NPPB), and device implanted. Categorical and continuous variables were compared using Chi‐squared and Wilcoxon rank‐sum tests, respectively. Of the 29 patients who received mechanical support, 17 (58.6%) were discharged home, 11 (37.9%) died during their hospitalization, and 1 (3.5%) remains hospitalized. Median length of ventricular assist device support was 59.5 days (range 1–653 days). Between December 1991 and December 2011, in‐hospital mortality was 64.3%. Following this period, significant changes were made to patient management with in‐hospital mortality decreasing to 13.3% between February 2013 and December 2015. Comparison between deceased and living patients revealed several significant factors including: median number of packed red blood cells transfused, 8 versus 4 units (P = 0.048), median OR time, 396 versus 299 min (P = 0.003), and device implanted. During the early stages of the mechanical support program, higher than expected mortality rates prompted changes in the management of pediatric cardiac patients, specifically, the development of a dedicated management team. These changes significantly improved outcomes and we suggest can be used as a model for similar cardiac support programs, especially in smaller volume programs.</description><identifier>ISSN: 0160-564X</identifier><identifier>EISSN: 1525-1594</identifier><identifier>DOI: 10.1111/aor.12963</identifier><identifier>PMID: 29105103</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Bilirubin ; Child ; Child, Preschool ; Congenital ; Continuous flow ; Creatinine ; Erythrocytes ; Extracorporeal membrane oxygenator ; Female ; Heart ; Heart - physiopathology ; Heart Defects, Congenital - mortality ; Heart Defects, Congenital - physiopathology ; Heart Defects, Congenital - surgery ; Heart diseases ; Heart Failure - mortality ; Heart Failure - physiopathology ; Heart Failure - surgery ; Heart transplantation ; Heart-Assist Devices - adverse effects ; Heart‐assist devices ; Hospital Mortality ; Hospitals, University - statistics &amp; numerical data ; Humans ; Infant ; Intubation ; Iowa - epidemiology ; Length of Stay - statistics &amp; numerical data ; Male ; Management ; Mechanical circulatory support ; Mortality ; Patients ; Pediatric heart failure ; Pediatrics ; Program Evaluation ; Pulsatile Flow ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Ventricle ; Ventricular assist devices</subject><ispartof>Artificial organs, 2018-04, Vol.42 (4), p.444-451</ispartof><rights>2018 International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-66898183581423dd9b5e9c708d8c3b0b7ea589dd7b7a7c1c23d81df09fbac87f3</citedby><cites>FETCH-LOGICAL-c3533-66898183581423dd9b5e9c708d8c3b0b7ea589dd7b7a7c1c23d81df09fbac87f3</cites><orcidid>0000-0002-7356-905X ; 0000-0003-1636-6501</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Faor.12963$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faor.12963$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29105103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kashyap, Abhishek</creatorcontrib><creatorcontrib>Turek, Joseph W.</creatorcontrib><creatorcontrib>Wagner, Samantha J.</creatorcontrib><creatorcontrib>Felderman, Laura</creatorcontrib><creatorcontrib>Jaggers, Elizabeth A.</creatorcontrib><creatorcontrib>Gruber, Peter J.</creatorcontrib><creatorcontrib>Edens, R. Erik</creatorcontrib><title>Development of a Pediatric Cardiac Mechanical Support Program</title><title>Artificial organs</title><addtitle>Artif Organs</addtitle><description>The development of a pediatric cardiac support program is a complex, multidisciplinary project. This study describes the University of Iowa Congenital Heart Program's experience from its inception to the present. In, we examine those specific factors that have led to substantial improvements in the program, additionally identifying where further gains can be made. We retrospectively reviewed all pediatric patients who received mechanical cardiac support at the University of Iowa from the inception of the program in 1991. In total, 29 patients received mechanical support between December 1991 and December 2015 and are included in the study. Twelve patients received continuous flow devices and 17 patients received pulsatile flow devices. Median age at implant was 12.8 years (range 0.1–18.2 years). Median weight at implant was 40.5 kg (3.2–123.4 kg). Factors examined included: operating room (OR) time, intensive care unit and hospital length of stay, intubation days, blood product usage, pre‐ and post‐operative bilirubin, creatinine, natriuretic peptide B (NPPB), and device implanted. Categorical and continuous variables were compared using Chi‐squared and Wilcoxon rank‐sum tests, respectively. Of the 29 patients who received mechanical support, 17 (58.6%) were discharged home, 11 (37.9%) died during their hospitalization, and 1 (3.5%) remains hospitalized. Median length of ventricular assist device support was 59.5 days (range 1–653 days). Between December 1991 and December 2011, in‐hospital mortality was 64.3%. Following this period, significant changes were made to patient management with in‐hospital mortality decreasing to 13.3% between February 2013 and December 2015. Comparison between deceased and living patients revealed several significant factors including: median number of packed red blood cells transfused, 8 versus 4 units (P = 0.048), median OR time, 396 versus 299 min (P = 0.003), and device implanted. During the early stages of the mechanical support program, higher than expected mortality rates prompted changes in the management of pediatric cardiac patients, specifically, the development of a dedicated management team. These changes significantly improved outcomes and we suggest can be used as a model for similar cardiac support programs, especially in smaller volume programs.</description><subject>Adolescent</subject><subject>Bilirubin</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Congenital</subject><subject>Continuous flow</subject><subject>Creatinine</subject><subject>Erythrocytes</subject><subject>Extracorporeal membrane oxygenator</subject><subject>Female</subject><subject>Heart</subject><subject>Heart - physiopathology</subject><subject>Heart Defects, Congenital - mortality</subject><subject>Heart Defects, Congenital - physiopathology</subject><subject>Heart Defects, Congenital - surgery</subject><subject>Heart diseases</subject><subject>Heart Failure - mortality</subject><subject>Heart Failure - physiopathology</subject><subject>Heart Failure - surgery</subject><subject>Heart transplantation</subject><subject>Heart-Assist Devices - adverse effects</subject><subject>Heart‐assist devices</subject><subject>Hospital Mortality</subject><subject>Hospitals, University - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Infant</subject><subject>Intubation</subject><subject>Iowa - epidemiology</subject><subject>Length of Stay - statistics &amp; numerical data</subject><subject>Male</subject><subject>Management</subject><subject>Mechanical circulatory support</subject><subject>Mortality</subject><subject>Patients</subject><subject>Pediatric heart failure</subject><subject>Pediatrics</subject><subject>Program Evaluation</subject><subject>Pulsatile Flow</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Ventricle</subject><subject>Ventricular assist devices</subject><issn>0160-564X</issn><issn>1525-1594</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1LwzAYB_AgipvTg19ACl700C1pmjQ5eBjzFZQNX8BbSJNUO9qlJq2yb2-004NgLk8OP_48zx-AQwTHKLyJtG6MEk7xFhgikpAYEZ5ugyFEFMaEps8DsOf9EkKYpZDugkHCESQI4iE4OzfvprJNbVZtZItIRgujS9m6UkUz6cJXRXdGvcpVqWQVPXRNY10bLZx9cbLeBzuFrLw52MwReLq8eJxdx7fzq5vZ9DZWmGAcU8o4QwwThtIEa81zYrjKINNM4RzmmZGEca2zPJOZQioYhnQBeZFLxbICj8BJn9s4-9YZ34q69MpUlVwZ23mBOA3XpGmKAz3-Q5e2c6uwnUhgQiHnCLOgTnulnPXemUI0rqylWwsExVenInQqvjsN9miT2OW10b_yp8QAJj34KCuz_j9JTOf3feQnpLp-bg</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Kashyap, Abhishek</creator><creator>Turek, Joseph W.</creator><creator>Wagner, Samantha J.</creator><creator>Felderman, Laura</creator><creator>Jaggers, Elizabeth A.</creator><creator>Gruber, Peter J.</creator><creator>Edens, R. Erik</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7356-905X</orcidid><orcidid>https://orcid.org/0000-0003-1636-6501</orcidid></search><sort><creationdate>201804</creationdate><title>Development of a Pediatric Cardiac Mechanical Support Program</title><author>Kashyap, Abhishek ; Turek, Joseph W. ; Wagner, Samantha J. ; Felderman, Laura ; Jaggers, Elizabeth A. ; Gruber, Peter J. ; Edens, R. Erik</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-66898183581423dd9b5e9c708d8c3b0b7ea589dd7b7a7c1c23d81df09fbac87f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescent</topic><topic>Bilirubin</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Congenital</topic><topic>Continuous flow</topic><topic>Creatinine</topic><topic>Erythrocytes</topic><topic>Extracorporeal membrane oxygenator</topic><topic>Female</topic><topic>Heart</topic><topic>Heart - physiopathology</topic><topic>Heart Defects, Congenital - mortality</topic><topic>Heart Defects, Congenital - physiopathology</topic><topic>Heart Defects, Congenital - surgery</topic><topic>Heart diseases</topic><topic>Heart Failure - mortality</topic><topic>Heart Failure - physiopathology</topic><topic>Heart Failure - surgery</topic><topic>Heart transplantation</topic><topic>Heart-Assist Devices - adverse effects</topic><topic>Heart‐assist devices</topic><topic>Hospital Mortality</topic><topic>Hospitals, University - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Infant</topic><topic>Intubation</topic><topic>Iowa - epidemiology</topic><topic>Length of Stay - statistics &amp; numerical data</topic><topic>Male</topic><topic>Management</topic><topic>Mechanical circulatory support</topic><topic>Mortality</topic><topic>Patients</topic><topic>Pediatric heart failure</topic><topic>Pediatrics</topic><topic>Program Evaluation</topic><topic>Pulsatile Flow</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Ventricle</topic><topic>Ventricular assist devices</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kashyap, Abhishek</creatorcontrib><creatorcontrib>Turek, Joseph W.</creatorcontrib><creatorcontrib>Wagner, Samantha J.</creatorcontrib><creatorcontrib>Felderman, Laura</creatorcontrib><creatorcontrib>Jaggers, Elizabeth A.</creatorcontrib><creatorcontrib>Gruber, Peter J.</creatorcontrib><creatorcontrib>Edens, R. Erik</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Artificial organs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kashyap, Abhishek</au><au>Turek, Joseph W.</au><au>Wagner, Samantha J.</au><au>Felderman, Laura</au><au>Jaggers, Elizabeth A.</au><au>Gruber, Peter J.</au><au>Edens, R. Erik</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a Pediatric Cardiac Mechanical Support Program</atitle><jtitle>Artificial organs</jtitle><addtitle>Artif Organs</addtitle><date>2018-04</date><risdate>2018</risdate><volume>42</volume><issue>4</issue><spage>444</spage><epage>451</epage><pages>444-451</pages><issn>0160-564X</issn><eissn>1525-1594</eissn><abstract>The development of a pediatric cardiac support program is a complex, multidisciplinary project. This study describes the University of Iowa Congenital Heart Program's experience from its inception to the present. In, we examine those specific factors that have led to substantial improvements in the program, additionally identifying where further gains can be made. We retrospectively reviewed all pediatric patients who received mechanical cardiac support at the University of Iowa from the inception of the program in 1991. In total, 29 patients received mechanical support between December 1991 and December 2015 and are included in the study. Twelve patients received continuous flow devices and 17 patients received pulsatile flow devices. Median age at implant was 12.8 years (range 0.1–18.2 years). Median weight at implant was 40.5 kg (3.2–123.4 kg). Factors examined included: operating room (OR) time, intensive care unit and hospital length of stay, intubation days, blood product usage, pre‐ and post‐operative bilirubin, creatinine, natriuretic peptide B (NPPB), and device implanted. Categorical and continuous variables were compared using Chi‐squared and Wilcoxon rank‐sum tests, respectively. Of the 29 patients who received mechanical support, 17 (58.6%) were discharged home, 11 (37.9%) died during their hospitalization, and 1 (3.5%) remains hospitalized. Median length of ventricular assist device support was 59.5 days (range 1–653 days). Between December 1991 and December 2011, in‐hospital mortality was 64.3%. Following this period, significant changes were made to patient management with in‐hospital mortality decreasing to 13.3% between February 2013 and December 2015. Comparison between deceased and living patients revealed several significant factors including: median number of packed red blood cells transfused, 8 versus 4 units (P = 0.048), median OR time, 396 versus 299 min (P = 0.003), and device implanted. During the early stages of the mechanical support program, higher than expected mortality rates prompted changes in the management of pediatric cardiac patients, specifically, the development of a dedicated management team. These changes significantly improved outcomes and we suggest can be used as a model for similar cardiac support programs, especially in smaller volume programs.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29105103</pmid><doi>10.1111/aor.12963</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-7356-905X</orcidid><orcidid>https://orcid.org/0000-0003-1636-6501</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0160-564X
ispartof Artificial organs, 2018-04, Vol.42 (4), p.444-451
issn 0160-564X
1525-1594
language eng
recordid cdi_proquest_miscellaneous_1961034443
source MEDLINE; Access via Wiley Online Library
subjects Adolescent
Bilirubin
Child
Child, Preschool
Congenital
Continuous flow
Creatinine
Erythrocytes
Extracorporeal membrane oxygenator
Female
Heart
Heart - physiopathology
Heart Defects, Congenital - mortality
Heart Defects, Congenital - physiopathology
Heart Defects, Congenital - surgery
Heart diseases
Heart Failure - mortality
Heart Failure - physiopathology
Heart Failure - surgery
Heart transplantation
Heart-Assist Devices - adverse effects
Heart‐assist devices
Hospital Mortality
Hospitals, University - statistics & numerical data
Humans
Infant
Intubation
Iowa - epidemiology
Length of Stay - statistics & numerical data
Male
Management
Mechanical circulatory support
Mortality
Patients
Pediatric heart failure
Pediatrics
Program Evaluation
Pulsatile Flow
Retrospective Studies
Time Factors
Treatment Outcome
Ventricle
Ventricular assist devices
title Development of a Pediatric Cardiac Mechanical Support Program
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T18%3A56%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20Pediatric%20Cardiac%20Mechanical%20Support%20Program&rft.jtitle=Artificial%20organs&rft.au=Kashyap,%20Abhishek&rft.date=2018-04&rft.volume=42&rft.issue=4&rft.spage=444&rft.epage=451&rft.pages=444-451&rft.issn=0160-564X&rft.eissn=1525-1594&rft_id=info:doi/10.1111/aor.12963&rft_dat=%3Cproquest_cross%3E2026099138%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2026099138&rft_id=info:pmid/29105103&rfr_iscdi=true